Northstar Asset Management Inc. Acquires 5,619 Shares of Novo Nordisk A/S (NYSE:NVO)

Northstar Asset Management Inc. grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 3.9% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 148,376 shares of the company’s stock after acquiring an additional 5,619 shares during the period. Novo Nordisk A/S comprises 3.0% of Northstar Asset Management Inc.’s holdings, making the stock its 12th largest holding. Northstar Asset Management Inc.’s holdings in Novo Nordisk A/S were worth $10,303,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Park Square Financial Group LLC acquired a new stake in shares of Novo Nordisk A/S during the fourth quarter worth $29,000. Transce3nd LLC acquired a new stake in shares of Novo Nordisk A/S during the fourth quarter worth $33,000. North Capital Inc. acquired a new stake in shares of Novo Nordisk A/S during the first quarter worth $27,000. Copeland Capital Management LLC increased its position in shares of Novo Nordisk A/S by 184.8% during the first quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock worth $27,000 after buying an additional 255 shares during the period. Finally, Stone House Investment Management LLC acquired a new stake in shares of Novo Nordisk A/S during the first quarter worth $30,000. Institutional investors own 11.54% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on NVO. Wall Street Zen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. BNP Paribas upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research report on Wednesday. UBS Group cut shares of Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a report on Tuesday, August 5th. Hsbc Global Res cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 31st. Finally, Dbs Bank cut shares of Novo Nordisk A/S to a “sell” rating in a report on Friday, April 25th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $83.75.

Novo Nordisk A/S Trading Up 2.9%

NYSE:NVO opened at $52.43 on Friday. The stock has a market capitalization of $234.10 billion, a price-to-earnings ratio of 14.40, a PEG ratio of 1.80 and a beta of 0.63. The firm has a fifty day simple moving average of $64.96 and a two-hundred day simple moving average of $70.34. Novo Nordisk A/S has a 12 month low of $45.05 and a 12 month high of $139.74. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.93 by $0.04. The firm had revenue of $11.69 billion during the quarter, compared to analysts’ expectations of $77.51 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. Analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th will be issued a dividend of $0.4119 per share. This represents a dividend yield of 240.0%. The ex-dividend date is Monday, August 18th. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 22.53%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.